DE69923671D1 - Verwendung von kannabidiol als entzündunghemmende mittel - Google Patents
Verwendung von kannabidiol als entzündunghemmende mittelInfo
- Publication number
- DE69923671D1 DE69923671D1 DE69923671T DE69923671T DE69923671D1 DE 69923671 D1 DE69923671 D1 DE 69923671D1 DE 69923671 T DE69923671 T DE 69923671T DE 69923671 T DE69923671 T DE 69923671T DE 69923671 D1 DE69923671 D1 DE 69923671D1
- Authority
- DE
- Germany
- Prior art keywords
- cannabidiol
- inflammatory agent
- cannabinoids
- inflammatory diseases
- treating inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 2
- 229950011318 cannabidiol Drugs 0.000 title abstract 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title 1
- 229930003827 cannabinoid Natural products 0.000 abstract 3
- 239000003557 cannabinoid Substances 0.000 abstract 3
- 229940065144 cannabinoids Drugs 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9807639 | 1998-04-14 | ||
GBGB9807639.1A GB9807639D0 (en) | 1998-04-14 | 1998-04-14 | Anti-inflammatory agents |
PCT/GB1999/001140 WO1999052524A1 (en) | 1998-04-14 | 1999-04-14 | Use of cannabinoids as anti-inflammatory agents |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69923671D1 true DE69923671D1 (de) | 2005-03-17 |
DE69923671T2 DE69923671T2 (de) | 2006-03-16 |
Family
ID=10830115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69923671T Expired - Lifetime DE69923671T2 (de) | 1998-04-14 | 1999-04-14 | Verwendung von cannabidiol als entzündunghemmende mittel |
Country Status (12)
Country | Link |
---|---|
US (1) | US6410588B1 (de) |
EP (1) | EP1071417B1 (de) |
JP (1) | JP2002511411A (de) |
AT (1) | ATE288749T1 (de) |
AU (1) | AU757945B2 (de) |
CA (1) | CA2328368C (de) |
DE (1) | DE69923671T2 (de) |
DK (1) | DK1071417T3 (de) |
ES (1) | ES2241277T3 (de) |
GB (1) | GB9807639D0 (de) |
IL (1) | IL138979A0 (de) |
WO (1) | WO1999052524A1 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512188A (ja) | 1998-04-21 | 2002-04-23 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 抗酸化剤及び神経保護剤としてのカンナビノイド類 |
US6274635B1 (en) | 1999-03-22 | 2001-08-14 | Immugen Pharmaceuticals Inc. | Alkylated resorcinol derivatives for the treatment of immune diseases |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
US7473681B2 (en) | 2000-10-31 | 2009-01-06 | Pharma Mar, S.A. | Kahalalide F |
EP1206934A1 (de) * | 2000-11-15 | 2002-05-22 | B. Braun Melsungen Ag | Blockade von Natriumkanälen mit Phenolderivaten |
US10004684B2 (en) | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
GB0202385D0 (en) * | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
WO2003063847A1 (en) * | 2002-02-01 | 2003-08-07 | Gw Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
EP1487436A4 (de) | 2002-03-08 | 2009-06-03 | Signal Pharm Inc | Kombinationstherapie zur behandlung, prävention oder versorgung von proliferativen erkrankungen und krebs |
MXPA05001567A (es) * | 2002-08-14 | 2005-04-25 | Gw Pharma Ltd | Formulaciones liquidas de canabinoides para la administracion a traves de la mucosa. |
US7067155B2 (en) * | 2003-01-03 | 2006-06-27 | Tbni, Inc. | Anti-inflammatory humate compositions and methods of use thereof |
IL160420A0 (en) * | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
US20080262079A1 (en) * | 2004-08-09 | 2008-10-23 | Bernard Mach | Cannabinoid Compositions and Methods of Use Thereof |
US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
EP2007376B1 (de) | 2006-03-13 | 2013-05-08 | Hadasit Medical Research Services And Development Ltd. | Therapeutische verwendungen von cannabidiol-verbindungen |
GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
GB2450741A (en) * | 2007-07-05 | 2009-01-07 | Gw Pharma Ltd | Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease |
ATE493977T1 (de) * | 2007-10-02 | 2011-01-15 | Vivacell Biotechnology Espana S L | Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen |
GB2496688B (en) | 2011-11-21 | 2016-06-29 | Gw Pharma Ltd | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases |
US9889100B2 (en) | 2013-05-02 | 2018-02-13 | Mor Research Applications Ltd. | Cannabidiol for treatment of severe and refractory graft-versus-host disease |
ES2788744T3 (es) | 2013-05-02 | 2020-10-22 | Mor Research Applic Ltd | Cannabidiol para la prevención y el tratamiento de la enfermedad de injerto contra huésped |
US10172786B2 (en) * | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
EP3277260B1 (de) | 2015-04-01 | 2021-05-12 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Pflanzenextrakte aus erodium crassifolium l'her und verwendungen davon |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
US20180296521A1 (en) * | 2015-10-16 | 2018-10-18 | Scythian Biosciences Inc. | Methods and compositions for treating gastrointestinal inflammation |
WO2017160923A1 (en) * | 2016-03-15 | 2017-09-21 | Royal Oil Colorado Llc | Formulations of argan oil and cannabidiol |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
US10399920B2 (en) | 2016-06-01 | 2019-09-03 | S&B Pharma, Inc. | Crystalline form of cannabidiol |
GB2551985B (en) * | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
US20190314297A1 (en) | 2016-11-02 | 2019-10-17 | To Pharmaceuticals Llc | Combination therapy of cbd and copaxone |
IL269158B2 (en) | 2017-03-05 | 2024-04-01 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Cannabis preparations enriched with THCA and their use for the treatment of inflammatory diseases |
CA3068879C (en) * | 2017-07-18 | 2022-12-13 | Deyi Pharmaceutical Ltd. | Use of cannabidol in treatment of pulmonary hypertension |
WO2019034985A1 (en) * | 2017-08-14 | 2019-02-21 | Zynerba Pharmaceuticals, Inc. | METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL |
US10945982B1 (en) * | 2018-05-03 | 2021-03-16 | Paul A. Lobel | Nasal hygiene method and composition |
US11110056B1 (en) | 2018-05-03 | 2021-09-07 | Actual Natural Health & Wellness Products, Inc. | Nasal hygiene method and composition |
CA3116858A1 (en) * | 2018-10-16 | 2020-04-23 | Systamedic Inc. | Novel compositions for the treatment of inflammatory diseases |
US11026888B1 (en) | 2019-01-04 | 2021-06-08 | Nutrition Therapeutics, Inc. | Functional beverage compositions and methods of using and making same |
JP7364839B2 (ja) * | 2019-01-24 | 2023-10-19 | 漢義生物科技(北京)有限公司 | 創傷治癒を促進する医薬品の製造におけるカンナフラビンaの使用 |
EP3923915A4 (de) * | 2019-02-11 | 2023-03-22 | John Robert Chancey | Verfahren zur herstellung und verwendung von phytocannabinoiden in einem komplex mit einem protein, peptid, aminosäure, polysaccharid, disaccharid oder monosaccharid |
EP3962296A4 (de) * | 2019-04-30 | 2023-02-08 | Greenway Herbal Products, LLC | Cannabinoidzusammensetzungen und verfahren zur verwendung |
AU2020315475A1 (en) * | 2019-07-18 | 2022-02-03 | Direct Biologics Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
WO2021195691A1 (en) * | 2020-04-02 | 2021-10-07 | Incannex Healthcare Limited | Methods and compositions for treating or preventing an inflammatory condition |
AU2020447169A1 (en) * | 2020-05-11 | 2022-12-08 | Add Advanced Drug Delivery Technologies Ltd. | Uses and formulations of cannabinoids |
US20230172873A1 (en) * | 2020-05-11 | 2023-06-08 | Add Advanced Drug Delivery Technologies Ltd. | Uses and Formulations of Cannabinoids |
WO2022113071A2 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoid derivatives and their use the treatment of inflammation and/or pain and/or obesity |
AU2022309612A1 (en) * | 2021-07-15 | 2024-02-01 | Incannex Healthcare Limited | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule |
EP4230201A1 (de) | 2022-02-21 | 2023-08-23 | Universidade Nova De Lisboa | Zusammensetzungen zur behandlung von neurodegenerativen erkrankungen |
WO2023156983A1 (en) | 2022-02-21 | 2023-08-24 | Universidade Nova De Lisboa | Compounds and compositions for neurodegenerative diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL48824A (en) * | 1976-01-12 | 1980-05-30 | Yissum Res Dev Co | Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type |
US4847290A (en) * | 1987-08-17 | 1989-07-11 | Sumner Burstein | Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents |
US4973603A (en) * | 1988-06-16 | 1990-11-27 | Sumner Burstein | Platelet activating factor antagonist and methods of use therefor |
US5521215A (en) | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
US5338753A (en) * | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
-
1998
- 1998-04-14 GB GBGB9807639.1A patent/GB9807639D0/en not_active Ceased
-
1999
- 1999-04-14 DK DK99915942T patent/DK1071417T3/da active
- 1999-04-14 JP JP2000543134A patent/JP2002511411A/ja active Pending
- 1999-04-14 CA CA002328368A patent/CA2328368C/en not_active Expired - Fee Related
- 1999-04-14 DE DE69923671T patent/DE69923671T2/de not_active Expired - Lifetime
- 1999-04-14 US US09/673,207 patent/US6410588B1/en not_active Expired - Lifetime
- 1999-04-14 AU AU34361/99A patent/AU757945B2/en not_active Ceased
- 1999-04-14 AT AT99915942T patent/ATE288749T1/de not_active IP Right Cessation
- 1999-04-14 WO PCT/GB1999/001140 patent/WO1999052524A1/en active IP Right Grant
- 1999-04-14 EP EP99915942A patent/EP1071417B1/de not_active Expired - Lifetime
- 1999-04-14 ES ES99915942T patent/ES2241277T3/es not_active Expired - Lifetime
- 1999-04-14 IL IL13897999A patent/IL138979A0/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2002511411A (ja) | 2002-04-16 |
DK1071417T3 (da) | 2005-06-13 |
GB9807639D0 (en) | 1998-06-10 |
ES2241277T3 (es) | 2005-10-16 |
IL138979A0 (en) | 2001-11-25 |
WO1999052524A1 (en) | 1999-10-21 |
CA2328368A1 (en) | 1999-10-21 |
US6410588B1 (en) | 2002-06-25 |
ATE288749T1 (de) | 2005-02-15 |
CA2328368C (en) | 2009-03-31 |
EP1071417A1 (de) | 2001-01-31 |
AU3436199A (en) | 1999-11-01 |
AU757945B2 (en) | 2003-03-13 |
DE69923671T2 (de) | 2006-03-16 |
EP1071417B1 (de) | 2005-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69923671D1 (de) | Verwendung von kannabidiol als entzündunghemmende mittel | |
DK0882021T3 (da) | Nye phenanthridiner | |
BR9714385A (pt) | Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular | |
MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
DE69011305D1 (de) | Cyclopropylderivate als Lipoxygenase-Inhibitoren. | |
NO994330D0 (no) | Metode for behandling av en tumor | |
ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
DE69705421D1 (de) | 15-fluoro-prostaglandine als augendrucksenkende mittel | |
DE69902520T2 (de) | Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden | |
DE60226953D1 (de) | Linderung von akrochordon | |
BG101126A (en) | The use of muramylpeptide compounds | |
ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
DE69905602T2 (de) | Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren | |
MXPA02004699A (es) | Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco. | |
DE60109594D1 (de) | R-eliprodil zur behandlung von glaucoma | |
LV11593A (lv) | Dimetikona pielietojums aizcietejumu arstesana | |
BR0015424A (pt) | Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco | |
UA36485A (uk) | Спосіб лікування генералізованого пародонтиту | |
DK1017377T3 (da) | Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande | |
ATE271878T1 (de) | Verwendung von protein h als zytostattischer wirkstoff | |
UA6151U (en) | Method for treating experimental burns | |
UA32360A (uk) | Спосіб лікування розповсюджених хронічних дерматозів | |
UA38987A (uk) | Спосіб лікування піодермії | |
CO5271719A1 (es) | Composicion cosmetica adelgazante que contienen una substancia inductora de la produccion de il-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |